作者
Chengjin Ye, Kevin Chiem, Jun-Gyu Park, Fatai Oladunni, Roy Nelson Platt, Tim Anderson, Fernando Almazan, Juan Carlos de la Torre, Luis Martinez-Sobrido
发表日期
2020/10/27
期刊
MBio
卷号
11
期号
5
页码范围
10.1128/mbio. 02168-20
出版商
American Society for Microbiology
简介
Infectious coronavirus (CoV) disease 2019 (COVID-19) emerged in the city of Wuhan (China) in December 2019, causing a pandemic that has dramatically impacted public health and socioeconomic activities worldwide. A previously unknown coronavirus, severe acute respiratory syndrome CoV-2 (SARS-CoV-2), has been identified as the causative agent of COVID-19. To date, there are no U.S. Food and Drug Administration (FDA)-approved vaccines or therapeutics available for the prevention or treatment of SARS-CoV-2 infection and/or associated COVID-19 disease, which has triggered a large influx of scientific efforts to develop countermeasures to control SARS-CoV-2 spread. To contribute to these efforts, we have developed an infectious cDNA clone of the SARS-CoV-2 USA-WA1/2020 strain based on the use of a bacterial artificial chromosome (BAC). Recombinant SARS-CoV-2 (rSARS-CoV-2) was readily …
引用总数
2020202120222023202412429269
学术搜索中的文章